Dana-Farber Cancer Institute: CAR T-cell Therapy Generates Lasting Remissions in Patients With Multiple Myeloma
February 25, 2021
February 25, 2021
BOSTON, Feb. 25 -- The Dana-Farber Cancer Institute issued the following news release on Feb. 24, 2021:
In a major advance in the treatment of multiple myeloma, a CAR T-cell therapy has generated deep, sustained remissions in patients who had relapsed from several previous therapies, an international clinical trial has found.
In a study posted online today by the New England Journal of Medicine, trial leaders report that almost 75% of the participants responded to the t . . .
In a major advance in the treatment of multiple myeloma, a CAR T-cell therapy has generated deep, sustained remissions in patients who had relapsed from several previous therapies, an international clinical trial has found.
In a study posted online today by the New England Journal of Medicine, trial leaders report that almost 75% of the participants responded to the t . . .